Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -9.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 11.82 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 570.25 | — | — | — | 43.13 | — | — | — | 14.80 | 30.46 | 101.36 | 107.38 | 23.53 | 165.62 | 547.24 | 62.50 | 134.96 | 860.32 | — | 3.16 | 113.04 |
| — | — | — | — | +191.4% | — | — | — | -37.1% | -81.6% | -81.5% | +71.8% | -82.6% | -80.7% | — | +1875.2% | +19.4% | — | — | -99.2% | — | |
| P/B Ratio | 5.33 | 4.27 | 7.53 | 4.60 | 1.85 | 0.71 | 0.72 | 0.77 | 1.84 | 1.77 | 3.51 | 2.12 | 0.57 | 0.96 | 0.79 | 0.55 | 0.57 | 0.77 | 0.72 | 1.40 | 3.29 |
| — | +502.3% | +951.0% | +495.1% | +0.7% | -60.0% | -79.6% | -63.5% | +220.9% | +85.2% | +343.4% | +282.9% | -0.2% | +23.8% | +9.2% | -60.5% | -82.6% | -82.4% | -82.3% | -78.7% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 7.44 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 7.80 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -195.1% | — | — | — | -661.8% | — | — | — | 68.2% | 40.2% | 12.6% | -37.4% | -3429.3% | -9002.5% | -29140.4% | -5332.6% | -8797.2% | -45826.0% | — | 46.1% | -696.7% |
| — | — | — | — | -1070.4% | — | — | — | +102.0% | +100.4% | +100.0% | +99.3% | +61.0% | +80.4% | — | -11663.2% | -1162.7% | -10244.4% | — | +107.3% | -81.1% | |
| Operating Margin | -5150.8% | — | — | — | -1071.6% | — | — | — | -597.9% | -1427.1% | -1797.7% | -2654.2% | -4168.8% | -11373.5% | -38001.8% | -6737.4% | -11900.5% | -55316.0% | — | 30.7% | -925.3% |
| — | — | — | — | -79.2% | — | — | — | +85.7% | +87.5% | +95.3% | +60.6% | +65.0% | +79.4% | — | -22017.4% | -1186.2% | -9648.1% | — | +103.4% | -90.3% | |
| Net Margin | -4880.9% | — | — | — | -1005.6% | — | — | — | -556.4% | -1339.5% | -1659.6% | -2477.2% | -4014.7% | -10673.0% | -36357.9% | -6515.6% | -11620.3% | -54742.0% | — | 26.1% | -916.3% |
| — | — | — | — | -80.7% | — | — | — | +86.1% | +87.4% | +95.4% | +62.0% | +65.5% | +80.5% | — | -25074.9% | -1168.2% | -9915.0% | — | +102.9% | -88.6% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -60.3% | -9.9% | -16.6% | -14.3% | -13.4% | -20.0% | -18.6% | -21.2% | -16.1% | -18.0% | -13.5% | -13.7% | -21.9% | -14.4% | -12.4% | -13.5% | -11.7% | -11.6% | -9.4% | 2.9% | -6.5% |
| — | +50.6% | +11.0% | +32.4% | +16.8% | -11.1% | -37.6% | -54.3% | +26.6% | -24.9% | -9.0% | -1.5% | -87.8% | -24.2% | -31.8% | -559.5% | -80.5% | -41.6% | -142.6% | +130.8% | +83.4% | |
| ROA | -53.6% | -9.4% | -15.3% | -13.2% | -12.2% | -17.6% | -16.3% | -18.4% | -13.9% | -15.7% | -12.1% | -12.2% | -19.3% | -12.8% | -10.8% | -11.9% | -10.4% | -10.5% | -8.6% | 2.6% | -5.5% |
| — | +46.7% | +6.1% | +28.6% | +12.0% | -12.3% | -34.7% | -51.1% | +28.0% | -22.3% | -11.8% | -2.8% | -85.6% | -22.2% | -25.5% | -560.6% | -89.3% | -46.8% | -150.2% | +153.0% | +30.3% | |
| ROIC | -137.3% | -15.3% | -59.9% | -23.9% | -25.6% | -100.7% | -60.8% | -35.9% | -24.4% | -31.2% | -37.5% | -28.5% | -29.0% | -20.5% | -14.2% | -13.2% | -10.7% | -10.6% | -9.5% | 3.9% | -7.2% |
| — | +84.9% | +1.4% | +33.5% | -4.8% | -223.4% | -61.9% | -26.1% | +16.0% | -52.2% | -164.9% | -115.1% | -171.2% | -93.4% | -49.5% | -439.4% | -48.9% | -16.4% | -86.1% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.01 | 0.03 | 0.03 | 0.03 | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | — | — |
| — | -75.7% | -36.2% | -31.3% | -24.6% | +51.0% | +51.6% | +47.3% | -3.7% | +4.7% | +22.4% | +4.3% | +76.8% | +60.7% | +33.8% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.70 | 27.59 | 22.06 | 11.70 | 17.00 | 10.25 | 9.08 | 8.88 | 7.96 | 7.62 | 9.15 | 12.51 | 8.04 | 10.50 | 9.86 | 7.39 | 10.53 | 9.46 | 15.17 | 11.72 | 15.21 |
| — | +169.2% | +143.1% | +31.7% | +113.5% | +34.6% | -0.8% | -29.0% | -0.9% | -27.5% | -7.2% | +69.1% | -23.7% | +11.0% | -35.0% | -36.9% | -30.8% | -54.7% | -18.0% | -42.9% | +76.2% | |
| Quick Ratio | 11.70 | 27.59 | 22.06 | 11.70 | 17.00 | 10.25 | 9.08 | 8.88 | 7.96 | 7.62 | 9.15 | 12.51 | 8.04 | 10.50 | 9.86 | 7.39 | 10.53 | 9.46 | 15.17 | 11.72 | 15.21 |
| — | +169.2% | +143.1% | +31.7% | +113.5% | +34.6% | -0.8% | -29.0% | -0.9% | -27.5% | -7.2% | +69.1% | -23.7% | +11.0% | -35.0% | -36.9% | -30.8% | -54.7% | -18.0% | -42.9% | +76.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying STTK stock.
Shattuck Labs, Inc.'s current P/E is -9.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Shattuck Labs, Inc.'s current operating margin is -5150.8%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Shattuck Labs, Inc.'s business trajectory between earnings reports.